Price
Target price
€0.30
€0.30
-
-
-
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Tempramed Technologies Ltd. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Cons
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
News
TempraMed Expands Institutional Healthcare Network with Meuhedet Health Services, a Leading HMO in Israel, Covering Over 1 million Lives
Acceptance of TempraMed’s products by Meuhedet Health Services strengthens TempraMed's B2B institutional commercialization strategy as the Company advances reimbursement initiatives and
TempraMed Signs LOI for Exclusive Distribution in Kuwait, Expanding Presence in High-Growth Gulf Region Healthcare Market
Highlights
- TempraMed signs non-binding LOI for exclusive distribution in Kuwait with Elegir Trading
- Kuwait represents a high-value market with significant demand for
TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels
Integration into McKesson’s Medical-Surgical Solutions marketplace serving a nationwide customer base
Toronto, ON – June 30, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY)